Cargando…
Inhibitor repurposing reveals ALK, LTK, FGFR, RET and TRK kinases as the targets of AZD1480
Many tyrosine kinase inhibitors (TKIs) have failed to reach human use due to insufficient activity in clinical trials. However, the failed TKIs may still benefit patients if their other kinase targets are identified by providing treatment focused on syndromes driven by these kinases. Here, we search...
Autores principales: | Gudernova, Iva, Balek, Lukas, Varecha, Miroslav, Kucerova, Jana Fialova, Kunova Bosakova, Michaela, Fafilek, Bohumil, Palusova, Veronika, Uldrijan, Stjepan, Trantirek, Lukas, Krejci, Pavel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752523/ https://www.ncbi.nlm.nih.gov/pubmed/29312610 http://dx.doi.org/10.18632/oncotarget.22674 |
Ejemplares similares
-
One reporter for in-cell activity profiling of majority of protein kinase oncogenes
por: Gudernova, Iva, et al.
Publicado: (2017) -
Fibroblast growth factor receptor influences primary cilium length through an interaction with intestinal cell kinase
por: Kunova Bosakova, Michaela, et al.
Publicado: (2019) -
AZD1480 Blocks Growth and Tumorigenesis of RET- Activated Thyroid Cancer Cell Lines
por: Couto, Joana P., et al.
Publicado: (2012) -
The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma
por: Derenzini, E, et al.
Publicado: (2011) -
The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma
por: Derenzini, E, et al.
Publicado: (2014)